{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:14:59Z","timestamp":1758874499240,"version":"3.28.0"},"reference-count":32,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2024.14731","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T11:19:16Z","timestamp":1728472756000},"source":"Crossref","is-referenced-by-count":2,"title":["Good response of stage IV melanoma to high\u2011dose radiation therapy combined with immunotherapy: A case report"],"prefix":"10.3892","volume":"28","author":[{"given":"Xuemei","family":"Deng","sequence":"first","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kewei","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingting","family":"He","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingxi","family":"Guo","sequence":"additional","affiliation":[{"name":"Department Pathology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinglian","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongru","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"key20241112101940_b1-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"key20241112101940_b2-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3322\/caac.21609","article-title":"Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"70","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"key20241112101940_b3-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaad.2014.09.029","article-title":"Metastatic melanomas of unknown primary show better prognosis than those of known primary: A systematic review and meta-analysis of observational studies","volume":"72","author":"Bae","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"key20241112101940_b4-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"364","DOI":"10.6004\/jnccn.2021.0018","article-title":"NCCN guidelines\u00ae insights: Melanoma: Cutaneous, version 2.2021","volume":"19","author":"Swetter","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"key20241112101940_b5-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2478\/v10019-010-0008-x","article-title":"Role of radiotherapy in melanoma management","volume":"44","author":"Strojan","year":"2010","journal-title":"Radiol Oncol"},{"key":"key20241112101940_b6-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nri3902","article-title":"Immunological hallmarks of stromal cells in the tumour microenvironment","volume":"15","author":"Turley","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"key20241112101940_b7-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"key20241112101940_b8-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"e1440168","DOI":"10.1080\/2162402X.2018.1440168","article-title":"Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy","volume":"7","author":"Mohamad","year":"2018","journal-title":"Oncoimmunology"},{"key":"key20241112101940_b9-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ijrobp.2020.07.1741","article-title":"Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and anti-PD1 in mice and patients with non-small cell lung cancer","volume":"108","author":"Yin","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20241112101940_b10-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.radonc.2018.02.022","article-title":"Use of extracranial radiation therapy in metastatic melanoma patients receiving immunotherapy","volume":"127","author":"Gabani","year":"2018","journal-title":"Radiother Oncol"},{"key":"key20241112101940_b11-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1158\/2326-6066.CIR-18-0793","article-title":"Phase II trial of ipilimumab with stereotactic radiation therapy for metastatic disease: Outcomes, toxicities, and low-dose radiation-related abscopal responses","volume":"7","author":"Welsh","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"key20241112101940_b12-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1002\/ijc.32934","article-title":"Efficacy of late concurrent hypofractionated radiotherapy in advanced melanoma patients failing anti-PD-1 monotherapy","volume":"147","author":"Funck-Brentano","year":"2020","journal-title":"Int J Cancer"},{"key":"key20241112101940_b13-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: A pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir Med"},{"key":"key20241112101940_b14-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"key20241112101940_b15-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N Engl J Med"},{"key":"key20241112101940_b16-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: Evidence-based changes in the American joint committee on cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"key20241112101940_b17-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.clindermatol.2003.12.009","article-title":"Surgical margins for resection of primary cutaneous melanoma","volume":"22","author":"Cook","year":"2004","journal-title":"Clin Dermatol"},{"key":"key20241112101940_b18-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/bjd.13171","article-title":"Prognostic factors in localized invasive primary cutaneous malignant melanoma: Results of a large population-based study","volume":"172","author":"Eriksson","year":"2015","journal-title":"Br J Dermatol"},{"key":"key20241112101940_b19-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"196","DOI":"10.2174\/1874467208666150716120238","article-title":"Immunotherapy of melanoma","volume":"9","author":"Tarhini","year":"2016","journal-title":"Curr Mol Pharmacol"},{"key":"key20241112101940_b20-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"key20241112101940_b21-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"key20241112101940_b22-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"key20241112101940_b23-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","article-title":"The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity","volume":"71","author":"Burnette","year":"2011","journal-title":"Cancer Res"},{"key":"key20241112101940_b24-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ijrobp.2019.09.041","article-title":"Combined NK cell therapy and radiation therapy exhibit long-term therapeutic and antimetastatic effects in a human triple negative breast cancer model","volume":"108","author":"Kim","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20241112101940_b25-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00262-011-1172-6","article-title":"An immune-active tumor microenvironment favors clinical response to ipilimumab","volume":"61","author":"Ji","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"key20241112101940_b26-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"key20241112101940_b27-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"e1214788","DOI":"10.1080\/2162402X.2016.1214788","article-title":"Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma","volume":"5","author":"Liniker","year":"2016","journal-title":"Oncoimmunology"},{"key":"key20241112101940_b28-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","article-title":"Low-dose irradiation programs macrophage differentiation to an iNOS+\/M1 phenotype that orchestrates effective T cell immunotherapy","volume":"24","author":"Klug","year":"2013","journal-title":"Cancer Cell"},{"key":"key20241112101940_b29-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3389\/fimmu.2019.00193","article-title":"Role of radiation therapy in modulation of the tumor stroma and microenvironment","volume":"10","author":"Menon","year":"2019","journal-title":"Front Immunol"},{"key":"key20241112101940_b30-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ygyno.2021.03.017","article-title":"Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma","volume":"161","author":"Sezen","year":"2021","journal-title":"Gynecol Oncol"},{"key":"key20241112101940_b31-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1111\/ajco.12854","article-title":"Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Lee","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"key20241112101940_b32-ol-28-6-14731","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1470-2045(17)30171-7","article-title":"Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: An open-label, single arm, dual-centre, phase 2 clinical trial","volume":"18","author":"Schreuer","year":"2017","journal-title":"Lancet Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T08:19:53Z","timestamp":1731399593000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2024.14731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,10,9]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2024.14731","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"type":"print","value":"1792-1074"},{"type":"electronic","value":"1792-1082"}],"subject":[],"published":{"date-parts":[[2024,10,9]]},"article-number":"598"}}